Shares in Kenvue Inc (NYSE:KVUE) were up 9% in pre-market trading after the company exceeded Wall Street's expectations for second-quarter profit and revenue.
The consumer health company, spun off from Johnson & Johnson (NYSE:JNJ) last year, reported strong sales in its essential health products unit, which includes Tylenol, Listerine, and Neutrogena.
Overall, the topline number for the three months ended June 30 was $4 billion, beating the $3.94 billion forecast.
Adjusted profit was 32 cents per share, 4 cents higher than analysts' predictions. The company continues to project its annual adjusted profit to be between $1.10 and $1.20 per share.
Ahead of the bell, the stock was up $1.66 at $19.85.